A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept (BMS-224818)-Based Corticosteroid-Free Regimens in Renal Transplant.

Trial Profile

A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept (BMS-224818)-Based Corticosteroid-Free Regimens in Renal Transplant.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2014

At a glance

  • Drugs Belatacept (Primary) ; Antithymocyte globulin; Mycophenolate mofetil; Sirolimus; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Mar 2012 NCT reports planned end date as May 2012.
    • 15 Aug 2010 Results presented at the 23rd International Congress of the Transplantation Society.
    • 03 Aug 2010 Planned end date changed from Apr 2009 to Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top